Table 5

Medications (antirheumatic drugs and adjunct treatment) used during pregnancy (at least one reported use in any trimester). Categorical variables are expressed as numbers (percentages) and continuous variables as median (IQR)

All preg-nanciesRAPsASpAJIAUASLEPAPS – aPL carriersUCTDpSSSScIIMSVAnti-Ro/SSA carriers
Number of pregnancies866122694731121691351364128203818
Oral Glucocorticoids244 (28.2%)52 (42.6%)15 (21.7%)6 (12.8%)5 (16.1%)4 (33.3%)84 (49.7%)15 (11.1%)24 (17.6%)8 (19.5%)4 (14.3%)12
(60%)
12 (31.6%)3 (16.7%)
NSAIDs (regular use)10 (1.2%)1 (0.8%)2 (2.9%)4 (8.5%)0 (0%)1 (8.3%)1 (0.6%)1 (0.7%)0 (0%)0 (0%)0 (0%)0 (0%)0 (0%)0 (0%)
Hydroxychloroquine388
(44.8%)
59
(48.4%)
4
(5.8%)
1
(2.1%)
5
(16.1%)
3
(25%)
136 (80.5%)40
(29.6%)
82
(60.3%)
30
(73.2%)
6
(21.4%)
10
(50%)
1
(2.6%)
11
(61.1%)
csDMARDs *85 (9.8%)4 (3.3%)5 (5.8%)1 (2.1%)1 (3.2%)0 (0%)46 (27.2%)4 (3%)3 (2.2%)0 (0%)4 (14.3%)10 (50%)7 (18.4%)0 (0%)
bDMARDs *122 (14.1%)46 (37.7%)27 (39.1%)17 (36.2%)12 (38.7%)5 (41.7%)7 (4.1%)0 (0%)0 (0%)0 (0%)0 (0%)1 (5%)7 (18.4%)0 (0%)
tsDMARDs0 (0%)0 (0%)0 (0%)0 (0%)0 (0%)0 (0%)0 (0%)0 (0%)0 (0%)0 (0%)0 (0%)0 (0%)0 (0%)0 (0%)
Adjunct treatment
 LDASA566
(58.4%)
42
(34.4%)
27
(39.1%)
14
(29.8%)
10
(32.3%)
7
(58.3%)
123 (72.8%)115 (85.2%)83
(61%)
22
(53.7%)
20
(71.4%)
12
(60%)
23
(60.5%)
8
(44.4%)
 Heparin220
(25.4%)
10
(8.2%)
6
(8.7%)
2
(4.3%)
1
(3.2%)
1
(8.3%)
53
(31.4%)
107 (79.3%)23
(16.9%)
5
(12.2%)
1
(3.6%)
1
(5%)
8
(21.1%)
2
(11.1%)
 Folic acid694
(80.1%)
101 (82.8%)53
(76.8%)
34
(72.3%)
25
(80.6%)
7
(58.3%)
136 (80.5%)111 (82.2%)108 (79.4%)34
(82.9%)
24
(85.7%)
15
(75%)
32
(84.2%)
14
(77.8%)
 Vitamin D521
(60.2%)
69
(56.6%)
34
(49.3%)
25
(53.2%)
14
(45.2%)
7
(58.3%)
116 (68.6%)78
(57.8%)
83
(61%)
27
(65.9%)
17
(60.7%)
15
(75%)
28
(73.7%)
8
(44.4%)
  • *See online supplemental table 6 for details.

  • bDMARDs, biological DMARDs; csDMARDs, conventional synthetic DMARDs; DMARDs, disease-modifying antirheumatic drugs; IIM, idiopathic inflammatory myopathies; JIA, juvenile idiopathic arthritis; LDASA, low-dose acetylsalicylic acid; NSAIDs, non-steroidal anti-inflammatory drugs; PAPS, primary antiphospholipid syndrome; PsA, psoriatic arthritis; pSS, primary Sjögren’s syndrome; RA, rheumatoid arthritis; SLE, systemic lupus erythematosus; SpA, spondyloarthritis; SSc, systemic sclerosis; SV, systemic vasculitis; tsDMARDs, targeted synthetic DMARDs; UA, undifferentiated arthritis; UCTD, undifferentiated connective tissue disease.